Trial Profile

Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2019 According to an Orion media release, data from this trial was presented at the 30th International Symposium on ALS/MND in Perth, Australia last week
02 Dec 2019 According to a Orion media release, biomarker and pharmacokinetic data from this trial will be presented at the 30th International Symposium on ALS/MND held on 4-6 December 2019 in Perth, Australia.
26 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Orion media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com